Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in moderate/high-risk hospitalized COVID-19 patients
NCT04328480Phase 3Completed
- Sponsor
- ECLA
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of colchicine in coronavirus disease 2019 (COVID-19), sponsored by ECLA. Started Apr 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04328480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328480.